Thrombosis Drugs Market by Indication and Geography - Forecast and Analysis 2022-2026

Published: Mar 2022 Pages: 134 SKU: IRTNTR73016

The thrombosis drugs market share is expected to increase by USD 16.24 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 9.67%.

This thrombosis drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers thrombosis drugs market segmentation by indication (pulmonary embolism and DVT) and geography (North America, Europe, Asia, and Rest of World (ROW)). The thrombosis drugs market report also offers information on several market vendors, including Aspen Pharmacare Holdings Ltd., AuroMedics Pharma LLC, Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., GoodRx Holdings Inc., Grifols SA, GlaxoSmithKline Plc, Inari Medical Inc., Italfarmaco Spa, Johnson and Johnson, Pfizer Inc., Sanofi SA, Vasudha Pharma Chem Ltd., and Viatris Inc. among others.

What will the Thrombosis Drugs Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Thrombosis Drugs Market Size for the Forecast Period and Other Important Statistics

 

Thrombosis Drugs Market: Key Drivers, Trends, and Challenges

The introduction of novel oral anticoagulants is notably driving the thrombosis drugs market growth, although factors such as strong side-effects of anticoagulants may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the thrombosis drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Thrombosis Drugs Market Driver

One of the key factors driving the global thrombosis drugs industry growth is the introduction of novel oral anticoagulants. The market has witnessed the launch of a direct thrombin inhibitor called dabigatran and anti-Xa agents, including ELIQUIS (apixaban), SAVAYSA and LIXIANA (edoxaban), and XARELTO (rivaroxaban), that are classified as new-age oral anticoagulants. These novel oral anticoagulants have shown high efficacy and a higher safety profile for the treatment of thrombosis. They have higher efficacy compared with vitamin K antagonists as the dose does not need to be adjusted, and patients do not need to be monitored. Oral anticoagulants significantly reduce the risk of major bleeding. They have also been highly effective in the treatment of acute thrombosis. The development and launch of such drugs are expected to result in significant growth of the market during the forecast period.

Key Thrombosis Drugs Market Trend

Sedentary lifestyle is one of the key thrombosis drugs market trends that is expected to impact the industry positively in the forecast period. Old age and obesity are two of the most common causes of thrombosis. Globally, a sedentary lifestyle is resulting in an increase in the number of thrombosis cases. As per a study conducted by the Department of Biological Sciences, Dublin Institute of Technology, the average food consumption at a global level increased from 2,411 kcal per day in 1969 to 2,950 Kcal per day in 2015 and is expected to reach 3,040 kcal by 2030. The average food consumption in the US is significantly higher than the global rate and is about 3,750 kcal per day. The increase in sedentary behavior is leading to the rise in the prevalence of obesity across the world, thus increasing the risk of thrombosis. The increasing number of cases of thrombosis caused by these factors is expected to contribute to the growth of the market during the forecast years.

Key Thrombosis Drugs Market Challenge

One of the key challenges to the global thrombosis drugs industry growth is the strong side effects of anticoagulants. Anticoagulants decrease the ability of blood to clot, and they slow down the blood clotting process. As a result, the flow of blood becomes uncontrollable, even in cases of small cuts. The long-term use of anticoagulants is associated with increased cardiovascular risks, such as strokes and heart attacks. Some of the other side effects associated with the use of anticoagulants include severe bruising, prolonged nosebleeds, and vomiting blood. The use of anticoagulants is also associated with severe back pain, chest pain, dizziness, headaches, and jaundice. The increasing awareness of the side effects of anticoagulants is expected to hinder the growth of the global thrombosis drugs market during the forecast period.

This thrombosis drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global thrombosis drugs market as a part of the pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the thrombosis drugs market during the forecast period.

Who are the Major Thrombosis Drugs Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

  • Aspen Pharmacare Holdings Ltd.
  • AuroMedics Pharma LLC
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann La Roche Ltd.
  • GoodRx Holdings Inc.
  • Grifols SA
  • GlaxoSmithKline Plc
  • Inari Medical Inc.
  • Italfarmaco Spa
  • Johnson and Johnson
  • Pfizer Inc.
  • Sanofi SA
  • Vasudha Pharma Chem Ltd.
  • Viatris Inc.

 

This statistical study of the thrombosis drugs market encompasses successful business strategies deployed by the key vendors. The thrombosis drugs market is fragmented and the vendors are deploying growth strategies such as investment in R and D to compete in the market.

Product Insights and News

  • Aspen Pharmacare Holdings Ltd. - The company offers the thrombosis portfolio which is comprised largely of a broad range of specialist injectable anticoagulants. 
  • Aspen Pharmacare Holdings Ltd. - Under the manufacturing segment, the company offers heparin and non-heparin products. 

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The thrombosis drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Thrombosis Drugs Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the thrombosis drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Thrombosis Drugs Market?

For more insights on the market share of various regions Request for a FREE sample now!

44% of the market's growth will originate from North America during the forecast period. The US is the key market for thrombosis drugs in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).

The increasing prevalence of DVT and pulmonary embolism, the increasing awareness of the severity of the disease, and the advanced healthcare system will facilitate the thrombosis drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The ongoing COVID-19 outbreak positively impacted the growth of the regional thrombosis drugs market in 2020-2021, owing to the increasing need for anticoagulant treatment for patients with COVID-19-induced thrombosis indications. This has prompted vendors to increase production to meet the growing demand. Thus, the regional market in focus will register growth during the forecast period.

What are the Revenue-generating Indication Segments in the Thrombosis Drugs Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The thrombosis drugs market share growth by the pulmonary embolism segment will be significant during the forecast period. Advances in the pipeline of novel molecules and the approval of antidotes for oral anticoagulants are expected to significantly drive the growth of the segment during the forecast years.

This report provides an accurate prediction of the contribution of all the segments to the growth of the thrombosis drugs market size and actionable market insights on post COVID-19 impact on each segment.

 

Thrombosis Drugs Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 9.67%

Market growth 2022-2026

$ 16.24 billion

Market structure

Fragmented

YoY growth (%)

9.13

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 44%

Key consumer countries

US, France, Norway, UK, and Japan

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Aspen Pharmacare Holdings Ltd., AuroMedics Pharma LLC, Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., GoodRx Holdings Inc., Grifols SA, GlaxoSmithKline Plc, Inari Medical Inc., Italfarmaco Spa, Johnson and Johnson, Pfizer Inc., Sanofi SA, Vasudha Pharma Chem Ltd., and Viatris Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Thrombosis Drugs Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive thrombosis drugs market growth during the next five years
  • Precise estimation of the thrombosis drugs market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the thrombosis drugs industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of thrombosis drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Indication
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026
    • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
    • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
    • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
    • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary
    • Exhibit 17: Five forces analysis - Comparison between2021 and 2026
  • 4.2 Bargaining power of buyers
    • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
  • 4.3 Bargaining power of suppliers
    • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants
    • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes
    • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry
    • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
  • 4.7 Market condition
    • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Indication

  • 5.1 Market segments
    • Exhibit 24: Chart on Indication - Market share 2021-2026 (%)
    • Exhibit 25: Data Table on Indication - Market share 2021-2026 (%)
  • 5.2 Comparison by Indication
    • Exhibit 26: Chart on Comparison by Indication
    • Exhibit 27: Data Table on Comparison by Indication
  • 5.3 Pulmonary embolism - Market size and forecast 2021-2026
    • Exhibit 28: Chart on Pulmonary embolism - Market size and forecast 2021-2026 ($ million)
    • Exhibit 29: Data Table on Pulmonary embolism - Market size and forecast 2021-2026 ($ million)
    • Exhibit 30: Chart on Pulmonary embolism - Year-over-year growth 2021-2026 (%)
    • Exhibit 31: Data Table on Pulmonary embolism - Year-over-year growth 2021-2026 (%)
  • 5.4 DVT - Market size and forecast 2021-2026
    • Exhibit 32: Chart on DVT - Market size and forecast 2021-2026 ($ million)
    • Exhibit 33: Data Table on DVT - Market size and forecast 2021-2026 ($ million)
    • Exhibit 34: Chart on DVT - Year-over-year growth 2021-2026 (%)
    • Exhibit 35: Data Table on DVT - Year-over-year growth 2021-2026 (%)
  • 5.5 Market opportunity by Indication
    • Exhibit 36: Market opportunity by Indication ($ million)

6 Customer Landscape

  • 6.1 Customer landscape overview
    • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation
    • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
    • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
  • 7.2 Geographic comparison
    • Exhibit 40: Chart on Geographic comparison
    • Exhibit 41: Data Table on Geographic comparison
  • 7.3 North America - Market size and forecast 2021-2026
    • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
    • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
    • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
    • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • 7.4 Europe - Market size and forecast 2021-2026
    • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
    • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
    • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
    • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • 7.5 Asia - Market size and forecast 2021-2026
    • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
    • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
    • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
    • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
    • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
    • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
    • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • 7.7 US - Market size and forecast 2021-2026
    • Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
    • Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
    • Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
    • Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
  • 7.8 France - Market size and forecast 2021-2026
    • Exhibit 62: Chart on France - Market size and forecast 2021-2026 ($ million)
    • Exhibit 63: Data Table on France - Market size and forecast 2021-2026 ($ million)
    • Exhibit 64: Chart on France - Year-over-year growth 2021-2026 (%)
    • Exhibit 65: Data Table on France - Year-over-year growth 2021-2026 (%)
  • 7.9 Norway - Market size and forecast 2021-2026
    • Exhibit 66: Chart on Norway - Market size and forecast 2021-2026 ($ million)
    • Exhibit 67: Data Table on Norway - Market size and forecast 2021-2026 ($ million)
    • Exhibit 68: Chart on Norway - Year-over-year growth 2021-2026 (%)
    • Exhibit 69: Data Table on Norway - Year-over-year growth 2021-2026 (%)
  • 7.10 UK - Market size and forecast 2021-2026
    • Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
    • Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
    • Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
    • Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)
  • 7.11 Japan - Market size and forecast 2021-2026
    • Exhibit 74: Chart on Japan - Market size and forecast 2021-2026 ($ million)
    • Exhibit 75: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
    • Exhibit 76: Chart on Japan - Year-over-year growth 2021-2026 (%)
    • Exhibit 77: Data Table on Japan - Year-over-year growth 2021-2026 (%)
  • 7.12 Market opportunity by geography
    • Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges
    • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape
    • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption
    • Exhibit 81: Overview on factors of disruption
  • 9.4 Industry risks
    • Exhibit 82: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered
    • Exhibit 83: Vendors covered
  • 10.2 Market positioning of vendors
    • Exhibit 84: Matrix on vendor position and classification
  • 10.3 Aspen Pharmacare Holdings Ltd.
    • Exhibit 85: Aspen Pharmacare Holdings Ltd. - Overview
    • Exhibit 86: Aspen Pharmacare Holdings Ltd. - Business segments
    • Exhibit 87: Aspen Pharmacare Holdings Ltd. - Key offerings
    • Exhibit 88: Aspen Pharmacare Holdings Ltd. - Segment focus
  • 10.4 Baxter International Inc.
    • Exhibit 89: Baxter International Inc. - Overview
    • Exhibit 90: Baxter International Inc. - Business segments
    • Exhibit 91: Baxter International Inc. - Key news
    • Exhibit 92: Baxter International Inc. - Key offerings
    • Exhibit 93: Baxter International Inc. - Segment focus
  • 10.5 Boehringer Ingelheim International GmbH
    • Exhibit 94: Boehringer Ingelheim International GmbH - Overview
    • Exhibit 95: Boehringer Ingelheim International GmbH - Business segments
    • Exhibit 96: Boehringer Ingelheim International GmbH - Key news
    • Exhibit 97: Boehringer Ingelheim International GmbH - Key offerings
    • Exhibit 98: Boehringer Ingelheim International GmbH - Segment focus
  • 10.6 Bristol Myers Squibb Co.
    • Exhibit 99: Bristol Myers Squibb Co. - Overview
    • Exhibit 100: Bristol Myers Squibb Co. - Product / Service
    • Exhibit 101: Bristol Myers Squibb Co. - Key offerings
  • 10.7 Daiichi Sankyo Co. Ltd.
    • Exhibit 102: Daiichi Sankyo Co. Ltd. - Overview
    • Exhibit 103: Daiichi Sankyo Co. Ltd. - Business segments
    • Exhibit 104: Daiichi Sankyo Co. Ltd. - Key news
    • Exhibit 105: Daiichi Sankyo Co. Ltd. - Key offerings
    • Exhibit 106: Daiichi Sankyo Co. Ltd. - Segment focus
  • 10.8 F. Hoffmann La Roche Ltd.
    • Exhibit 107: F. Hoffmann La Roche Ltd. - Overview
    • Exhibit 108: F. Hoffmann La Roche Ltd. - Business segments
    • Exhibit 109: F. Hoffmann La Roche Ltd. - Key news
    • Exhibit 110: F. Hoffmann La Roche Ltd. - Key offerings
    • Exhibit 111: F. Hoffmann La Roche Ltd. - Segment focus
  • 10.9 GlaxoSmithKline Plc
    • Exhibit 112: GlaxoSmithKline Plc - Overview
    • Exhibit 113: GlaxoSmithKline Plc - Business segments
    • Exhibit 114: GlaxoSmithKline Plc - Key news
    • Exhibit 115: GlaxoSmithKline Plc - Key offerings
    • Exhibit 116: GlaxoSmithKline Plc - Segment focus
  • 10.10 Johnson and Johnson
    • Exhibit 117: Johnson and Johnson - Overview
    • Exhibit 118: Johnson and Johnson - Business segments
    • Exhibit 119: Johnson and Johnson - Key news
    • Exhibit 120: Johnson and Johnson - Key offerings
    • Exhibit 121: Johnson and Johnson - Segment focus
  • 10.11 Pfizer Inc.
    • Exhibit 122: Pfizer Inc. - Overview
    • Exhibit 123: Pfizer Inc. - Product / Service
    • Exhibit 124: Pfizer Inc. - Key news
    • Exhibit 125: Pfizer Inc. - Key offerings
  • 10.12 Sanofi SA
    • Exhibit 126: Sanofi SA - Overview
    • Exhibit 127: Sanofi SA - Business segments
    • Exhibit 128: Sanofi SA - Key news
    • Exhibit 129: Sanofi SA - Key offerings
    • Exhibit 130: Sanofi SA - Segment focus

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist
    • Exhibit 131: Inclusions checklist
    • Exhibit 132: Exclusions checklist
  • 11.3 Currency conversion rates for US$
    • Exhibit 133: Currency conversion rates for US$
  • 11.4 Research methodology
    • Exhibit 134: Research methodology
    • Exhibit 135: Validation techniques employed for market sizing
    • Exhibit 136: Information sources
  • 11.5 List of abbreviations
    • Exhibit 137: List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases

DATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts

REPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape

PURCHASE FULL REPORT OF

thrombosis drugs market market

QUICK BUY

Key Questions Answered

  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis